Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Device Center Faces New Charge Of Whistleblower Retaliation

This article was originally published in The Gray Sheet

Executive Summary

Federal officials took steps last week to reinstate a recently fired reviewer in FDA's diagnostics office, claiming that agency actions may have violated the Whistleblower Protection Act.

You may also be interested in...



FDA Email Surveillance Generates Court Battle And Image Problem

FDA’s biggest battle could be in the court of public opinion as employees claim the agency targeted and suppressed them based on their viewpoints and conducted intrusive searches and seizures. FDA says the surveillance began after a device industry attorney complained that a firm’s confidential information had been released.

FDA Email Surveillance Generates Court Battle And Image Problem

FDA’s biggest battle could be in the court of public opinion as employees claim the agency targeted and suppressed them based on their viewpoints and conducted intrusive searches and seizures. FDA says the surveillance began after a device industry attorney complained that a firm’s confidential information had been released.

FDA Email Spying: Crisis Experts Say Agency Needs To Tell Its Story Better

OIG has launched an investigation of FDA’s pre-market review process after the Office of Special Counsel concluded that two devices approved over the objection of FDA scientists likely pose imminent risk to public.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel